Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
Abstract The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12713 |
| _version_ | 1817997384232206336 |
|---|---|
| author | Marcely Gimenes Bonatto Rodrigo Albanez Vera Maria Cury Salemi Lídia Zytynski Moura |
| author_facet | Marcely Gimenes Bonatto Rodrigo Albanez Vera Maria Cury Salemi Lídia Zytynski Moura |
| author_sort | Marcely Gimenes Bonatto |
| collection | DOAJ |
| description | Abstract The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM initially refractory to gold standard treatment and afterwards treated with sacubitril/valsartan and its improvements. This is a case report of a 48‐year‐old woman, presenting with NCCM heart failure, who had received standard guideline‐directed medical therapy for 18 months without any improvement in clinical and echocardiographic parameters. After that period, sacubitril/valsartan was initiated. After 18 months of refractory usage of guideline‐directed medical therapy, sacubitril/valsartan was started, and significant change in functional class (III to I) and important ventricular remodelling were achieved with an improvement of 29% in the ejection fraction, reduction of 7 mm in ventricular diastolic diameter, and mild to none mitral valve functional regurgitation. In this case report, sacubitril/valsartan use was associated with improvement of echocardiographic and clinical parameters in a patient with NCCM. |
| first_indexed | 2024-04-14T02:36:16Z |
| format | Article |
| id | doaj.art-0d14aecaf34741e4adc8edb6caf13b01 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-04-14T02:36:16Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-0d14aecaf34741e4adc8edb6caf13b012022-12-22T02:17:22ZengWileyESC Heart Failure2055-58222020-06-01731186118910.1002/ehf2.12713Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case reportMarcely Gimenes Bonatto0Rodrigo Albanez1Vera Maria Cury Salemi2Lídia Zytynski Moura3Department of Cardiology Heart Failure and Heart Transplantation Section of Santa Casa de Misericórdia Hospital Curitiba Paraná BrazilDepartment of Cardiology Heart Failure and Heart Transplantation Section of Santa Casa de Misericórdia Hospital Curitiba Paraná BrazilHeart Failure Section of Heart Institute (InCor) University of São Paulo Medical School São Paulo BrazilDepartment of Cardiology Pontifical Catholic University of Paraná Curitiba BrazilAbstract The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM initially refractory to gold standard treatment and afterwards treated with sacubitril/valsartan and its improvements. This is a case report of a 48‐year‐old woman, presenting with NCCM heart failure, who had received standard guideline‐directed medical therapy for 18 months without any improvement in clinical and echocardiographic parameters. After that period, sacubitril/valsartan was initiated. After 18 months of refractory usage of guideline‐directed medical therapy, sacubitril/valsartan was started, and significant change in functional class (III to I) and important ventricular remodelling were achieved with an improvement of 29% in the ejection fraction, reduction of 7 mm in ventricular diastolic diameter, and mild to none mitral valve functional regurgitation. In this case report, sacubitril/valsartan use was associated with improvement of echocardiographic and clinical parameters in a patient with NCCM.https://doi.org/10.1002/ehf2.12713Heart failurenon‐compaction cardiomyopathySacubitril/valsartanReverse remodelling |
| spellingShingle | Marcely Gimenes Bonatto Rodrigo Albanez Vera Maria Cury Salemi Lídia Zytynski Moura Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report ESC Heart Failure Heart failure non‐compaction cardiomyopathy Sacubitril/valsartan Reverse remodelling |
| title | Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report |
| title_full | Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report |
| title_fullStr | Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report |
| title_full_unstemmed | Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report |
| title_short | Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report |
| title_sort | use of sacubitril valsartan in non compaction cardiomyopathy a case report |
| topic | Heart failure non‐compaction cardiomyopathy Sacubitril/valsartan Reverse remodelling |
| url | https://doi.org/10.1002/ehf2.12713 |
| work_keys_str_mv | AT marcelygimenesbonatto useofsacubitrilvalsartaninnoncompactioncardiomyopathyacasereport AT rodrigoalbanez useofsacubitrilvalsartaninnoncompactioncardiomyopathyacasereport AT veramariacurysalemi useofsacubitrilvalsartaninnoncompactioncardiomyopathyacasereport AT lidiazytynskimoura useofsacubitrilvalsartaninnoncompactioncardiomyopathyacasereport |